Safety monitoring during the first month of the COVID-19 national vaccination program shows “reassuring safety profiles” for the Pfizer and Moderna COVID-19 vaccines, the Centers for Disease Control and Prevention reported today.

Emergency use authorizations for the vaccines require providers to report adverse events to the Vaccine Adverse Event Reporting System. About 91% of VAERS reports between Dec. 14, 2020, and Jan. 13, 2021, were for non-serious events and involved local and systemic symptoms, the authors said. Reported cases of anaphylaxis, a life-threatening but treatable allergic reaction, totaled 4.5 per million doses administered, comparable with those reported for other vaccines, they said.

The 113 deaths reported to VAERS over the period were consistent with expected all-cause mortality and did not suggest a causal relationship with vaccination, the authors said.

Related News Articles

Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…